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Abstract
Background: Statin-associated necrotizing myopathy (SANM) is a rare autoimmune disorder caused by administration of
statins. SANM is characterized by weakness due to necrosis and regeneration of myofibers. Here we report the first case of
SANM with acute respiratory failure treated with noninvasive pressure support ventilation in addition to
immunosuppressants.
Case presentation: A 59-year-old woman who had been treated with 2.5mg/day of rosuvastatin calcium for 5 years
stopped taking the drug 4months before admission to our hospital due to elevation of creatine kinase (CK). Withdrawal of
rosuvastatin for 1month did not decrease the level of CK, and she was admitted to our hospital due to the development of
muscle weakness of her neck and bilateral upper extremities. Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase
antibodies were positive. Magnetic resonance imaging showed myositis, and muscle biopsy from the right biceps brachii
muscle showed muscle fiber necrosis and regeneration without inflammatory cell infiltration, suggesting SANM. After the
diagnosis, she received methylprednisolone pulse therapy (mPSL, 1 g/day × 3 days, twice) and subsequent oral prednisolone
therapy (PSL, 30mg/day for 1month, 25mg/day for 1month and 22.5mg/day for 1month), leading to improvement of her
muscle weakness. One month after the PSL tapering to 20mg/day, her muscle weakness deteriorated with oxygen
desaturation (SpO2: 93% at room air) due to hypoventilation caused by weakness of respiratory muscles. BIPAP was used for
the management of acute respiratory failure in combination with IVIG (20 g/day × 5 days) followed by mPSL pulse therapy
(1 g/day × 3 days), oral PSL (30mg/day × 3weeks, then tapered to 25mg/day) and tacrolimus (3mg/day). Twenty-seven
days after the start of BIPAP, she was weaned from BIPAP with improvement of muscle weakness, hypoxemia and
hypercapnia. After she achieved remission with improvement of muscle weakness and reduction of serum CK level to a
normal level, the dose of oral prednisolone was gradually tapered to 12.5mg/day without relapse for 3months.
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Conclusions: Our report provides new insights into the role of immunosuppressants and biphasic positive airway pressure
for induction of remission in patients with SANM.
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Background
Statin-associated necrotizing myopathy (SANM), charac-
terized by symmetrical weakness and muscle enzyme el-
evations as a consequence of necrosis and regeneration
of myofibers, is a rare disease that occurs in patients
treated with statins [1–3]. Previous studies suggested that
statins enhance the expression of 3-hydroxy-3-methylglutaryl
coenzyme A reductase (HMGCR), the enzymatic target of
statins, in genetically susceptible patients, leading to the de-
velopment of disease-specific antibodies against HMGCR
[4–9]. SANM causes life-threatening hypoventilation-
mediated hypoxemia and hypercapnia, but therapeutic strat-
egies for SANM have not been established yet.
Noninvasive pressure support ventilation (NIPSV) is
the delivery of mechanical ventilation to the lungs with-
out an endotracheal airway by biphasic positive airway
pressure (BIPAP) that is applied with two levels of pres-
sure, inspiratory positive airway pressure (IPAP) and ex-
piratory positive airway pressure (EPAP) [10]. The
patient’s inspiratory effort triggers the ventilator to de-
liver a decelerated flow to achieve and maintain a preset
pressure, while ventilatory assistance ceases when the
patient’s inspiratory flow falls. This modality is useful for
patients with hypoxemia and/or hypercapnia due to
acute respiratory failure, leading to a reduction of the in-
tubation rate and mortality.
Here we report the first serious case of SANM compli-
cated with hypoxemia and hypercapnia. Combined med-
ications of glucocorticoids, immunosuppressants and
intravenous immunoglobulins (IVIG) in addition to ven-
tilatory support with a BIPAP device were required to
control disease activity and acute respiratory failure
without unexpected side effects including infections.
Case presentation
A 59-year-old woman who had been diagnosed with
hyperlipidemia and treated with 2.5 mg/day of rosuvasta-
tin calcium for 5 years stopped taking the drug 4 months
before admission to our hospital due to elevation of cre-
atine kinase (CK, 1200 U/L; normal, 41–153 U/L). With-
drawal of rosuvastatin for 1 month did not decrease the
level of CK (> 2000 U/L), and she was admitted to our
hospital due to the development of muscle weakness of
her neck and bilateral upper extremities. Manual muscle
testing (MMT) revealed marked muscle weakness of her
neck and her paraspinal and bilateral upper extremities
(proximal>distal) with normal muscle tone, reflexes but
varying power (neck: 4, shoulder abductors: 4/4, elbow
flexors: 4/4, elbow extensors: 4/4, wrist extensors: 5/4,
hip flexors: 3/3, knee extensors: 5/5, knee flexors: 4/4,
ankle plantar flexors: 5/5). There was no evidence of
neurological signs or symptoms of the cerebellar and
autonomic systems. She had no skin rashes as exempli-
fied by dermatomyositis. Laboratory data showed
leukocytosis (10,200/μL; normal, 3300–8600/μL), in-
creased serum levels of muscle enzymes including CK
(2212 U/L), myoglobin (Mb, 2030 ng/ml; normal, 18–70
ng/ml) and aldolase (58.1 U/L; normal, 2.7–7.5 U/L) and
increased C-reactive protein (CRP) level (1.17 mg/dL;
normal, < 0.15 mg/dL) (Table 1). Tests for autoanti-
bodies including antinuclear antibody, rheumatoid fac-
tor, anti-Ro/SSA antibody and anti-La/SSB antibody
were negative, while disease-specific anti-HMGCR anti-
bodies for necrotizing myopathy were positive (3.9 IU/
mL) (Table 1). A computed tomography (CT) scan of
the chest, abdomen, and pelvis showed no remarkable
findings including infection, interstitial pneumonia and
malignancy. Magnetic resonance imaging (MRI) showed
high signal intensity on short-TI inversion recovery (STIR)
T2-weighted imaging in the left biceps brachii muscle and
triceps brachii muscle (Fig. 1a and b). A muscle biopsy from
the right biceps brachii muscle showed a mixture of muscle
fiber necrosis and regeneration without inflammatory cell in-
filtration (Fig. 1c-e). These findings suggested the existence
of SANM. After admission and diagnosis, she received meth-
ylprednisolone pulse therapy (mPSL, 1 g/day × 3 days, twice)
and subsequent oral prednisolone therapy (PSL, 30mg/day)
for 1 month, leading to improvement of her muscle weak-
ness with reduction of the serum level of CK (449U/L) (Fig.
1f). PSL was tapered to 25mg/day (for 1month) and 22.5
mg/day (for 1month) before tapering to 20mg/day.
One month after the PSL tapering to 20mg/day, her
muscle weakness deteriorated with elevation of CK level
(717U/L) (Fig. 1f, Relapse) and oxygen desaturation (SpO2:
93% at room air). Arterial blood gas analysis showed severe
hypoxia and hypercapnia due to hypoventilation caused by
weakness of respiratory muscles, and BIPAP was used for
the management of acute respiratory failure in combination
with IVIG (20 g/day × 5 days) followed by mPSL pulse ther-
apy (1 g/day × 3 days), oral PSL (30mg/day × 3weeks, then
tapered to 25mg/day) and tacrolimus (3mg/day) (Fig. 1f and
g). Twenty-seven days after the start of BIPAP, she was
weaned from BIPAP with improvement of muscle weakness,
hypoxemia and hypercapnia and reduction of the serum CK
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level (126U/L) to a normal level (Fig. 1f and g). After she
achieved remission, the dose of oral prednisolone was grad-
ually tapered to 12.5mg /day without relapse for 3months.
Discussion
During the course of the present case, we found that
glucocorticoid monotherapy is not sufficient to control
disease activity and that NIPSV is useful for the manage-
ment of hypoxemia and hypercapnia observed in patients
with SANM. SANM is classified as an autoimmune-
associated myopathy following abnormal production of
anti-HMGCR autoantibodies after statin medications, dif-
ferent from well-established polymyositis/dermatomyo-
sitis-associated antibodies against aminoacyl-tRNA
synthetases (ARS). Statin medications are one of the most
common therapeutic strategies for hyperlipidemia to re-
duce morbidity and mortality for both cardiovascular and
cerebral vascular diseases [1], whereas 5–20% of the pa-
tients stop taking a statin due to side effects including ele-
vation of serum CK level regardless of the presence or
absence of myalgia [11, 12]. While statin-related myopathy
is relieved after discontinuation of the statin in most cases,
2 or 3 of 100,000 statin-treated patients develop severe
myopathy that displays proximal muscle weakness and/or
muscle pain with elevation of CK level. It has been re-
ported that anti-HMGCR antibodies could induce muscle
weakness in mice through a complement-mediated mech-
anism [13]. However, the role of anti-HMGCR autoanti-
bodies in the pathogenesis of SANM has not been
clarified yet. Despite the presence of autoantibodies, nec-
rotic and regenerating myofibers without inflammatory in-
filtrates are predominantly observed in SANM, indicating
that the pathogenesis of SANM may be different from that
of common inflammatory myopathy, polymyositis/derm-
atomyositis. Consistent with these findings, glucocorticoid
monotherapy, which is initially used for polymyositis/
dermatomyositis, is not sufficient to control disease activ-
ity, and combination therapy of glucocorticoids and im-
munosuppressants is required for SANM [8, 14–16].
Other groups recommended triple therapy of glucocorti-
coids, immunosuppressants and IVIG [5] or rituximab [8]
for SANM. Our case demonstrates that treatment with
immunosuppressants and IVIG in addition to glucocorti-
coids is required for SANM patients complicated with
hypoxemia and hypercapnia due to acute respiratory fail-
ure. Further studies are needed to determine the optimal
treatment for patients with SANM.
In addition to the combination therapy, we used
NIPSV to control respiratory failure caused by SANM. A
previous study showed that half of the patients with
proximal myopathy had more than 50% reduction of
both inspiratory and expiratory muscle strengths and
Table 1 Laboratory data of the patient on admission
CRP C-reactive protein, RF rheumatoid factor, ANA anti-nuclear antibodies, Jo-1 anti-Jo-1 antibodies, ARS anti-aminoacyl-tRNA synthetase antibodies, HMGCR anti-3-
hydroxy-3-methylglutaryl coenzyme A reductase antibodies
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that hypercapnia was likely to occur when respiratory
muscle strength and vital capacity were less than 30% of
normal and 55% of the predicted value, respectively [17].
Previously, endotracheal intubation with a ventilator was
a major therapeutic strategy in patients with acute
respiratory failure who did not respond to conventional
treatment such as medications and oxygen. In addition
to complications related to the procedure of intubation
including local trauma, gastric content aspiration and
transient hypotension, intubated patients need complete
Fig. 1 a and b STIR T2-weighted imaging of MRI in the left proximal upper extremity (a sagittal imaging; b axial imaging). Red and yellow arrows
indicate the left biceps brachii muscle and triceps brachii muscle, respectively. c and d H&E staining at lower magnification (c) and higher
magnification (d) of muscle biopsy from the right biceps brachii muscle. e Another field image of H&E staining of the muscle biopsy from the
same muscle. Scale bars: 200 μm (c), 100 μm (d and e). Black arrows indicate a mixture of muscle fiber necrosis and regeneration without
inflammatory cell infiltration. f Clinical course of the patient showing serum levels of creatine kinase (CK, normal, 41–153 U/L). IVIG: intravenous
immunoglobulin. g Clinical course of the patient showing severe hypoxia and hypercapnia due to hypoventilation caused by weakness of
respiratory muscles. BIPAP was used for the management of acute respiratory failure, which dramatically improved after the commencement of
BIPAP support
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sedation, resulting in limited communication and further
muscle weakness. Moreover, those patients have a higher
risk of pneumonia, leading to higher mortality [18]. On
the other hand, a previous meta-analysis showed that
NIPSV reduces the intubation rate and mortality by 50
and 40%, respectively [18]. Therefore, NIPSV may be
recommended to control hypoxemia and hypercapnia
during the time before induction of remission and sub-
sequent improvement of respiratory muscles in patients
with SANM.
Conclusion
We reported a severe case of SANM complicated with re-
spiratory failure caused by weakness of respiratory mus-
cles. Our report provides new insights into the role of
immunosuppressants and biphasic positive airway pres-
sure for induction of remission in patients with SANM.
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